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LETTER TO THE EDITOR
Acute Vesico-Bullous Eruption from Methotrexate 
Overdose in a Psoriasis Patient
Hee Joo Kim, M.D., Sun Yae Kim, M.D., Sang Min Yi, M.D., Jae Hwan Kim, M.D., 
Il-Hwan Kim, M.D., Ph.D.
Department of Dermatology, Korea University Ansan Hospital, College of Medicine, Korea University, Ansan, Korea
Dear Editor:
Methotrexate (MTX) is a folic acid analog that potently 
blocks folate-dependent enzymes integral to DNA syn-
thesis
1. It is one of the most common systemic immuno-
suppressive agents used by dermatologists, particularly in 
the control of psoriasis. Fatal complications are rare in a 
dermatological low dose regimen. We herein report a case 
of acute cutaneous toxicity of MTX representing bullous 
eruption after a weekly dose of MTX was taken daily for a 
short period.
A 73-year-old male had been treated for psoriasis since 
2008 with narrow band ultraviolet B phototherapy. His 
psoriatic arthritis had been well controlled with etanercept 
subcutaneous injection for 1 year and he had stopped eta-
nercept for 1 year. MTX was considered after the psoriatic 
arthritis worsened, and a rheumatologist prescribed 10 
mg/week MTX for 5 days. He accidentally misunderstood 
the prescription and took 10 mg/day MTX for a period of 5 
days. After 1 week, he presented with erythematous vesi-
cobullae and erosions on the arms and face and ulcers in 
mucosal areas, including the lips (Fig. 1). There was no 
other skin disease history except psoriasis. Laboratory stu-
dies revealed thrombocytopenia (110,000/mm
3) and ala-
nine aminotransferase (ALT) was elevated to 99I U/L, 
whereas all laboratory data prior to MTX therapy, including 
complete blood count, liver function test, had been within 
normal limits. Other laboratory results including levels of 
albumin, blood urea nitrogen, and creatinine were within 
normal limits. With discontinuation of MTX and 
methylprednisolone 24 mg/day taken for a week, the skin 
bullous eruption and labial ulceration rapidly resolved 
without sequelae (Fig. 2), and the platelet count and ALT 
value returned to normal. Unfortunately, the patient refused 
pathologic evaluation. Clinical history, however, indicated 
MTX overdose-associated bullous eruption; the onset of the 
eruption was 5 days after initiation of MTX ingestion, and the 
eruption began to resolve immediately after discontinuation 
of MTX. After 2 weeks, MTX was restarted at a dose of 10 
mg/week and he is taking MTX without misunderstanding or 
adverse events. 
Although MTX’s precise mechanism of action in cutaneous 
autoimmune disease remains unclear, the effects are beli-
eved to include inhibition of cell division of tumoral, 
hematopoietic, and other rapidly proliferating cells
1. 
MTX has been associated with a number of mucocutaneous 
side effects, such as photosensitivity, erosions, necrolysis, 
and diffuse noninflammatory alopecia
1. More rarely, 
cutaneous ulceration within diseased skin has been 
reported
2,3. In this case, the latest psoriatic lesions of the 
patient were mainly on his arms, and the MTX cutaneous 
toxicity occurred on the diseased skin. Lawrence and Dahl
3 
reported that histologic evaluation of the ulcer edge showed 
swollen epidermal cells with vacuolated or dyskeratotic cells, 
indicating incipient epidermal necrolysis. Although rare, 
severe side effects, such as bone marrow suppression, liver 
failure, and pulmonary fibrosis can occur even in low-dose 
therapy 
4. 
As was the case in this instance, drugs available in once- 
weekly formulations require extra vigilance
5. One of the 
once-weekly dosing drugs, MTX, can be life-threatening 
when the drug is administered daily as a result of physician, HJ Kim, et al
108 Ann Dermatol
Fig. 1. Acute vesicobullous eruption
after administration of methotrexate
for 5 consecutive days (A) on oral 
mucosa (B) on the left arm.
Fig. 2. Ruptured bullous eruption healing with re-epithelization
on the left arm.
pharmacy, or patient error. Pre-MTX counseling needs to 
focus on ensuring that patients clearly understand this 
dosing schedule
1. In order to avoid a significant risk, pa-
tients should be given written, personalized information 
about the use of a once-weekly drug, and preparation of a 
time table can help the patient to establish a routine for 
taking doses as prescribed
5.
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